Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

LONDON, February 10, 2012 /PRNewswire/ --

-- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer --

-- Thomas Christély resigns as a Director of the Company --

Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, announces today the promotion of Tony Sedgwick PhD, FRCPath to the role of Chief Executive Officer from Chief Business Officer with immediate effect and the departure of Thomas Christély who has resigned as a Director of the Company for personal reasons but will ensure a smooth transition.

Dr Anthony David Sedgwick (aged 56) joined Silence in September 2011 to lead a new business development team and has been instrumental since then in helping shape the Company's future strategy and in discussions with partners, investors and other stakeholders.  Tony has extensive experience from European life science companies including more than fifteen years at Roche.  Prior to joining Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS.  He was also previously CEO of two successfully acquired companies, Daniolabs Ltd. and Cambridge Biotechnology Ltd.

Commenting on the announcement Jerry Randall, Chairman of Silence Therapeutics, said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry.  He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the Company continues to gain momentum. On behalf of the Board I would like to thank Thomas for his many years of valuable service to Silence and wish him well with his future endeavours. I am delighted that Tony has agreed to take on the CEO role. He has impressed us since joining and I am sure he will continue to do so."

Tony Sedgwick, newly promoted Chief Executive Officer, added: "Since joining Silence Therapeutics in September 2011, I have been excited by the Company and the opportunities that lie ahead.   We have a unique proprietary position in RNAi therapeutics and their delivery. I am confident that this will be further strengthened and will be the basis upon which investors and pharmaceutical partners alike will take an increasing interest in this Company. We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development. The Company's pipeline including  Atu027  is making good progress and is endorsed by external partners. I look forward to taking on the role of Chief Executive Officer and working with the staff at Silence to strengthen the Company's pipeline. Over the next few years, I intend to increase the commercial focus of the Company, harness the  RNAi therapeutics  opportunity and, as a result, create substantial shareholder value."

Tony Sedgwick holds 1,108,108 shares (0.19%) of the issued share capital in the Company.  No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules.

Notes for Editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutic candidates in the area of oncology. Atu027 incorporates two of the Company's technologies, AtuRNAi and AtuPLEX. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as repeated, intravenous administration. Encouraging interim safety and pharmacokinetic data were presented at the American Society of Clinical Oncology Annual Meeting in June 2011. The study is expected to be completed in the first half of 2012.

The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark, and Novartis/Quark. Silence is actively pursuing the establishment of additional partnerships. Silence Therapeutics has operations in both Berlin and London.

For further information, please contact:

Silence Therapeutics
Tony Sedgwick / Max Herrmann
+44-20-7491-6520
a.sedgwick@silence-therapeutics.com
m.herrmann@silence-therapeutics.com

M:Communications 
Mary-Jane Elliott / Claire Dickinson
+44-20-7920-2330
silencetherapeutics@mcomgroup.com

Singer Capital Markets
Shaun Dobson / Claes Spång
+44-20-3205-7500
shaun.dobson@singercm.com
claes.spang@singercm.com



'/>"/>
SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):